Long‐Standing Protection of Macaques Against Cell‐Free HIV‐2 With a HIV‐2 Iscom Vaccine
作者:
Per Putkonen,
Ewa Björling,
Lennart Åkerblom,
Rigmor Thorstensson,
Karin Lövgren,
Lena Benthin,
Francesca Chiodi,
Bror Morein,
Gunnel Biberfeld,
Erling Norrby,
Hans Wigzell,
期刊:
Journal of Acquired Immune Deficiency Syndromes
(OVID Available online 1994)
卷期:
Volume 7,
issue 6
页码: 551-559
ISSN:0894-9255
年代: 1994
出版商: OVID
关键词: HIV vaccine;HIV-2;Animal model;Iscoms;Cynomolgus monkeys
数据来源: OVID
摘要:
We investigated the capacity of two immunostimulating-complex (iscom) formulations including inactivated native HIV-2 viral proteins and selected peptides to induce protective immunity against HIV-2 in a nonhuman primate. Four cynomolgus monkeys were first immunized with five i.m. injections of purified detergent-disrupted HIV-2 virions (total dose, 0.7 mg) in iscoms over a period of 16 months. At months 18 and 20, all four macaques were given booster immunizations with iscom-coupled V3-derived synthetic peptides representing a dominating neutralizing region of HIV-2 gp125. Two weeks after the final dose of vaccine, the four vaccinated animals, together with four controls, were challenged i.v. with 10 monkey infectious doses (MID50) of monkey-cell–grown homologous cell-free virus, HIV-2SBL-6669/H5. After the challenge, the four control animals became readily infected; however, three of four vaccinated animals were protected as shown by repeated negative virus isolations and negative polymerase chain reaction for viral DNA and by failure to transmit HIV-2 infection with whole blood and lymph node cells into naive cynomolgus macaques. One of three protected animals showed an anamnestic antibody response to a dominating antigenic site, indicating possible limited virus replication. The vaccine-protected monkeys were subsequently resistant to rechallenge infection at 12, 15, and 18 months after the first challenge, suggesting that a reasonable duration of protective immunity had been induced by the vaccine.
点击下载:
PDF
(574KB)
返 回